| Nitric oxide synthase inhibitors in cardiogenic shock: present and future. | |
| | |
MedLine Citation:
|
PMID: 19804295 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
Cardiogenic shock (CS) accompanying myocardial infarction carries a case fatality rate of 40-50%. Profound myocardial dysfunction is partially reversible, and possibly related to a state of inflammatory storm accompanied by nitric oxide (NO) overproduction. CS survivors enjoy satisfactory longevity and quality of life. The focus of this review is to describe the available data regarding NO synthase (NOS) inhibitors in CS. In view of supportive evidence from mammalian research (inducible-NOS-knockout mice are less susceptible to ischemic and reperfusion injury), therapies mitigating NO overproduction were tested in human CS subjects. Human randomized clinical trials project excellent safety but lack of efficacy. Although the Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled Study to Assess the Safety and Efficacy of Tilarginine Acetate (L-N(G)-monomethyl arginine citrate [L-NMMA]) in CS (TRIUMPH) trial demonstrated lack of clinical benefit of 5-h infusion of L-NMMA in CS, major design issues regarding the optimal timing, dosing, duration and NOS inhibitor need to be addressed prior to rendering this therapy ineffective. |
| | |
Authors:
|
Edo Kaluski; Nir Uriel; Olga Milo-Cotter; Marc Klapholz |
Related Documents
:
|
947335 - Alterations of the frank orthogonal scalar leads induced by anaphylactic shock in the r... 15295725 - Efficacy of lower-energy biphasic shocks for transthoracic defibrillation: a follow-up ... 10931605 - Elective coronary stent implantation in cardiogenic shock complicating acute myocardial... 6471345 - Clinical usefulness of intraaortic balloon pumping in acute myocardial infarction compl... 19422595 - Successful transseptal catheter ablation of premature ventricular contractions arising ... 6092145 - Alpha-adrenergic tone in the coronary circulation of the conscious dog. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Future cardiology Volume: 4 ISSN: 1744-8298 ISO Abbreviation: Future Cardiol Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2009-10-06 Completed Date: 2009-12-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101239345 Medline TA: Future Cardiol Country: England |
Other Details:
|
Languages: eng Pagination: 183-9 Citation Subset: - |
Affiliation:
|
Director of Cardiac Catheterization Laboratories University Hospital and the University of Medicine & Dentistry, Department of Cardiology, 185 South Orange Ave, MSB I-538 Newark, NJ 07101, USA. ekaluski@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm.
Next Document: Future of cardiac resynchronization therapy.